Is BIOV.TA overvalued or undervalued?

BIOV.TA currently has a P/E ratio of -0.76. Relative to the sector average of 25.20, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Bio-View Ltd stock?

Bio-View Ltd trades on TLV. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of BIOV.TA?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying BIOV.TA protect my money against local inflation?

Many investors in Latin America buy international stocks like BIOV.TA to protect their purchasing power. Because BIOV.TA is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy BIOV.TA shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is BIOV.TA a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well BIOV.TA diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksBIOV.TA

Bio-View Ltd

₪70.90-₪1.24-1.72%

TLV / ILA

Market cap

₪10M

P/E

-0.8

EPS (TTM)

₪-29.90

Dividend yield

0.00%

Beta

-0.01

1Y return

-56.77%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$10M2021

$8M2022

$10M2023

$7M2024

$6M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.31Low
Current ratio1.62
Cash ratio0.59
Net margin-63.3%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

BIOV.TA-0.8
Healthcare sector median25.2
S&P 50022.0

Trades about 103% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.02
Price to book1.48
EPS (TTM)₪-29.90
Payout ratio0%
FCF yield-13.73%

Range & risk

₪0.71₪294.00

Trading in the lower third of its 52-week band

Beta-0.01

Profile

What Bio-View Ltd actually does

Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH (Fluorescence In Situ Hybridization) samples. Allegro Plus: Another automatic fluorescent imaging system engineered to pinpoint various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. DUET-3: An imaging and analysis platform featuring an automated barcode reader, which streamlines the processing of multiple test types within a single scan batch. DeNovo: An automated scanning system dedicated to the precise detection, analysis, and characterization of circulating tumor cells found in peripheral blood. Solo Workstation & Solo Touch Workstation: These are offline and standalone workstations, respectively, providing advanced tools for reviewing and analyzing test results remotely from the microscope. SoloWeb: A comprehensive web-based solution that enables remote analysis, reporting, and expert consultation on cases scanned using Bio-View's systems. Furthermore, Bio-View Ltd has established a strategic partnership with ANGLE plc to jointly develop a liquid biopsy circulating tumor cell HER2 assay, specifically targeting breast cancer.

CEO

Daniel Klain

Employees

Headquarters

Rehovot, HM

Founded

2006-03-12

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save BIOV.TA and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

BIOV.TA has a beta of -0.01, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Bio-View Ltd